incretin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Official Chinese resistance to opium was renewed on September 20, 1906, with an antiopium initiative intended to eliminate the drug problem within 10 years. The program relied on the turning of public sentiment against opium, with mass meetings at which opium paraphernalia were publicly burned, as well as coercive legal action and the granting of police powers to organizations such as the Fujian Anti-Opium Society. Smokers were required to register for licenses for gradually reducing rations of the drug. Action against opium farmers centered upon a highly repressive incarnation of law enforcement in which rural populations had their property destroyed, their land confiscated and/or were publicly tortured, humiliated and executed. Addicts sometimes turned to missionaries for treatment for their addiction, though many associated these foreigners with the drug trade. The program was counted as a substantial success, with a cessation of direct British opium exports to China (but not Hong Kong) and most provinces declared free of opium production. Nonetheless, the success of the program was only temporary, with opium use rapidly increasing during the disorder following the death of Yuan Shikai in 1916. Opium farming also increased, peaking in 1930 when the League of Nations singled China out as the primary source of illicit opium in East and Southeast Asia. Many local powerholders facilitated the trade during this period to finance conflicts over territory and political campaigns.
==== Elimination ==== The mean elimination half-life of carvedilol following oral administration ranges from 7 to 10 hours. The pharmaceutical product is a mix of two enantiomorphs, R(+)-carvedilol and S(–)-carvedilol, with differing metabolic properties. R(+)-Carvedilol undergoes preferential selection for metabolism, which results in a fractional half-life of about 5 to 9 hours, compared with 7 to 11 hours for the S(-)-carvedilol fraction.
== Pharmacokinetics == Maximum decrease in blood pressure occurs 4–6 hours after oral dosage. The half-life of methyldopa is 105 minutes. Methyldopa exhibits variable absorption from the gastrointestinal tract. It is metabolized in the liver and intestines and is excreted in urine.
=== May === 1 May – The FDA trade union announces plans to mount a legal challenge against the UK government's Safety of Rwanda Act amid concerns it breaches international law. MSPs vote 70–58 to defeat a motion of no confidence in the Scottish Government. 2 May – Local elections take place for councils and mayors in England and police and crime commissioners in England and Wales. The 2024 Blackpool South by-election is also held on the same day. John Swinney is set to become the next SNP leader and first minister after Kate Forbes confirms she will not seek the party's leadership. 3 May – With 90% of council election results announced, the Conservatives have lost over 400 council seats, while Labour regains control of Hartlepool, Redditch, Rushmoor and Thurrock Councils. Ben Houchen wins the Tees Valley mayoral election, retaining the seat for the Conservatives, while Labour win mayoral elections in the East Midlands, North East and York and North Yorkshire. Chris Webb wins the 2024 Blackpool South by-election, with a 26% swing to Labour. 2024 Peterborough City Council election: At 18, Daisy Creedon-Blakemore becomes the UK's youngest councillor after winning a seat for Labour in Peterborough City Council's Fletton and Woodston ward. 4 May 2024 London mayoral election: Labour's Sadiq Khan secures a third term as Mayor of London with 44% of the vote, beating the Conservative Susan Hall on 33%. 2024 West Midlands mayoral election: Labour's Richard Parker narrowly defeats the Conservative incumbent Andy Street to become Mayor of the West Midlands.
=== Flame ionization detector === Agilent FID (*.D/*.ch) FID Text (*.xy) NetCDF (*.cdf) PerkinElmer (*.raw) Varian (*.run) Finnigan FID (*.dat) Finnigan FID (*.raw) Shimadzu (*.gcd) Arw (*.arw) AnIML (*.animl) GAML (*.gaml) ...
Sources: en.wikipedia.org
This reaction is relatively slow, so even after significant exposure, the 239Pu is still mixed with a great deal of 238U (and possibly other isotopes of uranium), oxygen, other components of the original material, and fission products. Only if the fuel has been exposed for a few days in the reactor, can the 239Pu be chemically separated from the rest of the material to yield high-purity 239Pu metal. 239Pu has a higher probability for fission than 235U and a larger number of neutrons produced per fission event, so it has a smaller critical mass. Pure 239Pu also has a reasonably low rate of neutron emission due to spontaneous fission (10 fission/s·kg), making it feasible to assemble a mass that is highly supercritical before a detonation chain reaction begins. In practice, however, reactor-bred plutonium will invariably contain a certain amount of 240Pu due to the tendency of 239Pu to absorb an additional neutron during production. 240Pu has a high rate of spontaneous fission events (415,000 fission/s-kg), making it an undesirable contaminant. As a result, plutonium containing a significant fraction of 240Pu is not well-suited to use in nuclear weapons; it emits neutron radiation, making handling more difficult, and its presence can lead to a "fizzle" in which a small explosion occurs, destroying the weapon but not causing fission of a significant fraction of the fuel. It is because of this limitation that plutonium-based weapons must be implosion-type, rather than gun-type.
== Metabolism == The enzyme taxifolin 8-monooxygenase uses taxifolin, NADH, NADPH, H+, and O2 to produce 2,3-dihydrogossypetin, NAD+, NADP+, and H2O. The enzyme leucocyanidin oxygenase uses leucocyanidin, alpha-ketoglutarate, and O2 to produce cis-dihydroquercetin, taxifolin, succinate, CO2, and H2O.
The German Islands of Sylt, Föhr, Pellworm, Amrum, Heligoland and Fehmarn are part of Schleswig-Holstein, with the latter being the largest and the only Island of Schleswig-Holstein located on the east coast. Heligoland is Germany's only high-sea island.
== Uses == Gochujang is used in various dishes such as bibimbap and tteokbokki, and in salads, stews, soups, and marinated meat dishes. Gochujang may make dishes spicier (depending on the capsaicin in the base chili), but also can make them sweeter and smokier.
==== Olfactory stimuli ==== Olfactory stimuli are important for sexual reproduction and neuroendocrine function in many species. For instance, if a pregnant mouse is exposed to the urine of a 'strange' male during a critical period after coitus then the pregnancy fails (the Bruce effect). Thus, during coitus, a female mouse forms a precise 'olfactory memory' of her partner that persists for several days. Pheromonal cues aid synchronization of oestrus in many species; in women, synchronized menstruation may also arise from pheromonal cues, although the role of pheromones in humans is disputed.
Sources: en.wikipedia.org
French Guiana - Scouting in French Guiana Guadeloupe and Saint Martin - Scouting in Guadeloupe et Saint Martin Martinique - Scouts et Guides de Martinique Mayotte - Scouting in Mayotte New Caledonia - Scouting in New Caledonia Réunion - Scouting on Réunion Saint Pierre and Miquelon - Scouting in Saint Pierre and Miquelon Wallis and Futuna - Scouting in Wallis and Futuna New Zealand
=== Niche uses === Copper(II) sulfate has attracted many niche applications over the centuries. In industry copper sulfate has multiple applications. In printing it is an additive to book-binding pastes and glues to protect paper from insect bites; in building it is used as an additive to concrete to improve water resistance and prevent plant and mushroom growth. Copper sulfate can be used as a coloring ingredient in artworks, especially glasses and potteries. Copper sulfate is also rarely used in firework manufacture as a blue coloring agent, but it is not safe to mix copper(II) sulfate with metal powders, or it or any copper(II) compound with chlorates; the sulfate and other copper(II) compounds are not allowed in chlorate containing mixtures in the US.
=== Ratings === On FX, The Beauty premiered on January 21, 2026, drawing a total audience (P2+) of 512,400 viewers with a 0.16 rating, including 294,600 household viewers (0.23 rating). Subsequent episodes drew 297,900 viewers (0.09) on January 28, 183,000 (0.06) on February 4, and 206,000 (0.06) on February 11, followed by 266,000 viewers (0.08) on February 18 and 251,000 viewers (0.08) on February 25. The episode broadcast on March 4 drew 170,000 viewers (0.05), including 40,800 viewers aged 18–49 (0.03 rating), 37,700 viewers aged 25–54 (0.03 rating), and 166,500 household viewers (0.13 rating). Across this period, total viewership (P2+) ranged from 170,000 to 512,400 viewers, while ratings among adults aged 18–49 varied between 0.03 and 0.07. On streaming, The Beauty ranked No. 1 on Hulu's "Top 15 Today" list—a daily ranking of the platform's most-watched titles—on January 23, 2026, and remained on the chart through March 6, 2026.
== Synthesis == The first reported syntheses of fluoroalanine in 1976 involved treating cysteine with difluorine under an inert atmosphere. This produced a mixture of 3-fluoroalanine and 3,3-difluoroalanine, with the former as the major component.
Despite this toxicity, consumption of heavy water under normal circumstances does not pose a health threat to humans. It is estimated that a 70 kg (154 lb) person might drink 4.8 litres (1.3 US gal) of heavy water without serious consequences. Small doses of heavy water (a few grams in humans, containing an amount of deuterium comparable to that normally present in the body) are routinely used as harmless metabolic tracers in humans and animals.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.